Work

Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian cancer

Year: 2026

Type: article

Source: International Journal of Gynecological Cancer

DOI: 10.1016/j.ijgc.2025.104404

Authors: Robert M. Wenham, Sharad Ghamande, Ana Oaknin, Jonathan S. Berek, Jose Alejandro Perez-Fidalgo, Pau Guillén Sentís, Daniela Matei, Kan Yonemori, Mayu Yunokawa, Tingting Song, Natalyn Hawk, Rachael Scott, Vicky Makker

Institutions: Moffitt Cancer Center, Augusta University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Stanford Cancer Institute, Stanford University, Universitat de València, Hospital Clínico Universitario de Valencia, Institut Català d'Oncologia, National Cancer Center Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Eisai (United States), Eisai (United Kingdom), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eisai Canada

OpenAlex ID: W7129468925

FWCI:

Cites:

Cited by:

Related to: 10